scholarly journals Prognostic Implication of Preoperative Serum Albumin to Carcinoembryonic Antigen Ratio in Colorectal Cancer Patients

2021 ◽  
Author(s):  
Mingyue Xu ◽  
You Liu ◽  
Tianhui Xue ◽  
Qianwen Ye ◽  
Jia Xiang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Serum Albumin ◽  
Carcinoembryonic Antigen ◽  
Progression Free Survival ◽  
Distant Metastases ◽  
Rank Test ◽  
Lymphocyte To Monocyte Ratio ◽  
Preoperative Serum ◽  
Colorectal Cancer Patients

Abstract Both preoperative serum albumin (ALB) and carcinoembryonic antigen (CEA) were previously reported as useful prognostic factors in colorectal cancer (CRC); however, the ALB to CEA ratio (ACR) and their individual prognostic efficacies have been less studied. In this study, a total of 156 CRC patients staged I-IV were retrospectively enrolled. Patients were divided into ACR-low or ACR-high subgroups, and the differences in progression-free survival (PFS) and overall survival (OS) were conducted by Kaplan-Meier curves, log-rank test and Cox proportional model. As a result, a total of 31.41% (49/156) of patients presented with ACR-low disease, and these patients had tumors with advanced T stages (T3 + T4) (P<0.01), larger tumor diameters (P<0.01) and distant metastases (P = 0.01) and a relatively lower lymphocyte to monocyte ratio (LMR) (P<0.01). The ACR was significant in predicting survival. When 5.98 was used as the cutoff point, it had a sensitivity of 58.50% and 61.50% and a specificity of 83.50% and 80.50% for PFS and OS, respectively. ACR displayed a superior prognostic efficacy than other tested markers for both PFS and OS (except LMR). Patients in the ACR-low group displayed significantly worse PFS (log rank = 35.75, P<0.01) and OS (log rank = 29.68, P<0.01) than those in the ACR-high group. Finally, ACR was an independent prognostic factor for both PFS (HR = 0.31, 95% CI: 0.17–0.56, P < 0.01) and OS (HR = 0.33, 95% CI: 0.16–0.66, P < 0.01). For conclusion, the ACR was a robust prognostic factor in CRC, and patients with a relatively low preoperative ACR had significantly worse survival.

scholarly journals The prognostic role of tissue TLR2 and TLR4 in colorectal cancer

2020 ◽  
Vol 477 (5) ◽  
pp. 705-715
Author(s):  
Ines Beilmann-Lehtonen ◽  
Camilla Böckelman ◽  
Harri Mustonen ◽  
Selja Koskensalo ◽  
Jaana Hagström ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Distant Metastases ◽  
University Hospital ◽  
Rank Test ◽  
Pathogen Invasion ◽  
Kaplan Meier ◽  
Node Positive Disease ◽  
Colorectal Cancer Patients ◽  
Dukes C

Abstract Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors (TLRs) are crucial to detecting pathogen invasion and inducing the host’s immune response. This study aimed to explore the prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4 expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method, determining significance with the log-rank test. Among patients with lymph node–positive disease and no distant metastases (Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49–0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56–4.44, p < 0.001) compared with strong TLR2 immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-up, but further investigations are needed.

scholarly journals Hubungan Nilai Carcinoembryonic Antigen dengan Derajat Diferensiasi pada Karsinoma Kolorektal di RSUP Prof. Dr. R. D. Kandou Manado

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
John Wesley ◽  
Toar Mambu ◽  
Heber Sapan ◽  
Winfried M. Sumanti
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Correlation Study ◽  
North Sulawesi ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea ◽  
Differentiation Stage ◽  
Colorectal Cancer Patients

Abstract: Colorectal cancer is a serious health problem in Indonesia as well as in North Sulawesi. Serum carcinoembryonic antigen (CEA) is a progmostic factor in patients with this disease. This study was aimed to obtain the correlation between the histopathological differentiation stage and serum CEA level in colorectal cancer patients at Prof. Dr. R. D. Kandou Hospital Manado. This was an analytical correlation study. Subjects were colorectal cancer patients who had preoperative serum CEA level and histopathological differentiation stage results. Data were analyzed with Anova test (variant analysis) and Spearman Rho test. The results showed that there were 58 colorectal cancer patients enrolled in this study. The patients’ data were obtained from the Digestive Surgery clinic and nursery room of Prof. Dr. R. D. Kandou Hospital Manado. Of the 58 patients, 37 (63.79%) had moderate differentiated colorectal cancer. Related to serum CEA level, 23 patients (39.65%) had moderate differentiated colorectal cancer with serum CEA level 20-100 ng/ml. The Spearman Rho test showed that there was a positive correlation between serum CEA level and histopathoplogical differentiation stage of cancer (r = 0.877 and P = 0.001). Conclusion: There was a significant correlation between serum CEA level and histopathological differentiation stage of colorectal cancer. The better the differentiation stage, the higher the serum CEA level.Keywords: carcinoembryonic antigen, colorectal cancer, differentiation stageAbstrak: Karsinoma kolorektal (KKR) telah menjadi masalah kesehatan yang serius di Indonesia dan Sulawesi Utara pada khususnya. Kadar carcinoembryonic antigen (CEA) merupakan salah satu faktor prognostik pada penderita KKR. Penelitian ini bertujuan untuk mengetahui hubungan antara derajat diferensiasi histopatologik dengan kadar CEA dalam serum pada pasien KKR di RSUP Prof. Dr. R. D. Kandou Manado. Jenis penelitian ini ialah analitik korelatif. Subyek penelitian ialah 58 pasien KKR yang mempunyai hasil pemeriksaan kadar CEA serum preoperasi dan pemeriksaan derajat diferensiasi histopatologik. Analisis statistik menggunakan uji Anova (analisis variansi) dan korelasi Spearman Rho. Data pasien diambil dari pasien yang datang dan kontrol di Poliklinik Bedah Digestif serta dari ruang perawatan Bedah Digestif RSUP Prof. Dr. R. D. Kandou Manado. Hasil penelitian memperlihatkan derajat diferensiasi tumor kolorektal terbanyak ialah diferensiasi sedang/moderate differentiated yaitu 37 pasien (63,79%). Bila dihubungkan dengan nilai CEA serum, yang terbanyak ditemukan ialah jenis diferensiasi sedang pada pasien dengan kadar CEA serum 20-100 ng/ml sebanyak 23 orang (39,65%). Uji Spearman Rho memperlihatkan bahwa kadar CEA berkorelasi positif dengan derajat diferensiasi KKR (r = 0,877 dan P = 0,0001). Simpulan: Terdapat korelasi bermakna antara kadar CEA serum dan derajat diferensiasi kanker kolorektal. Derajat diferensiasi KKR yang baik memiliki kadar CEA yang tinggi.Kata kunci: carcinoembryonic antigen, karsinoma kolorektal, derajat differensiasi

scholarly journals Low Serum Interleukin-13 Levels Correlate with Poorer Prognoses for Colorectal Cancer Patients

2014 ◽  
Vol 99 (3) ◽  
pp. 223-229 ◽  
Author(s):  
Susumu Saigusa ◽  
Koji Tanaka ◽  
Yasuhiro Inoue ◽  
Yuji Toiyama ◽  
Yoshinaga Okugawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Poor Prognosis ◽  
Predictive Marker ◽  
Distant Metastases ◽  
Lymphatic Invasion ◽  
Enzyme Linked Immunosorbent Assay ◽  
Interleukin 13 ◽  
Preoperative Serum ◽  
Colorectal Cancer Patients ◽  
Low Serum

Abstract Interleukin-13 (IL-13) is an immunosuppressive cytokine produced by several immune cells and cancer cells. The aim of this retrospective study was to determine if serum IL-13 levels have an association with clinical outcome in patients with colorectal cancer. A total of 241 patients with colorectal cancer were enrolled in the present study. Preoperative serum IL-13 concentrations were measured by enzyme-linked immunosorbent assay. We analyzed the association of serum IL-13 levels with clinicopathological variables. Patients with lymph node metastasis, lymphatic invasion, vascular invasion, distant metastases or advanced stage of disease had significantly lower serum IL-13 levels. Low serum IL-13 was significantly associated with both poor recurrence-free and overall survival. Multivariate analysis showed that low IL-13 levels were an independent predictive marker for poor prognosis. In conclusion, our data suggest that low serum IL-13 levels may be a useful predictive marker for poor prognosis in colorectal cancer.

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS3617-TPS3617 ◽  
Author(s):  
Stefan Kasper ◽  
Gerrit zur Hausen ◽  
Alexander Stein ◽  
Sebastian Stintzing ◽  
Andreas Berger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomized Study ◽  
Progression Free Survival ◽  
Rank Test ◽  
Open Label ◽  
First Line Therapy ◽  
Kaplan Meier ◽  
Dismal Prognosis ◽  
Translational Research Program ◽  
Colorectal Cancer Patients

TPS3617 Background: Patients with metastatic colorectal cancer (mCRC) with progressive disease on/after or who are intolerant to fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic and anti-EGFR therapies have limited therapeutic options and a dismal prognosis, with a median survival below 6 months. Recently, Trifluridin/Tipiracil (TAS102) significantly improved survival in patients with refractory mCRC and ramucirumab has been approved in combination with FOLFIRI for the treatment of patients with mCRC after prior FOLFOX/bevacizumab first line therapy. Previous studies on both components provide a strong rationale to conduct a randomized study evaluating the efficacy and safety of ramucirumab in combination with TAS102 in patients with refractory mCRC to improve efficacy and prevent resistance. Methods: This is an interventional, randomized, open label, multicenter, phase IIb study in patients with advanced mCRC. Eligible patients will be randomized 1:1 and receive either ramucirumab and TAS102 (ramucirumab 8 mg/kg on d1+15, q4w and TAS102 35 mg/m² on d1-5 and d8-12, q4w) or TAS102 alone. Primary endpoint is overall survival as assessed by the Kaplan-Meier method, assuming a 6 months survival probability of 70% with ramucirumab in combination with TAS102 and 58% with TAS102 alone. Treatment groups are compared using the log-rank test. A total of 144 patients will be enrolled at 30 sites (1-sided alpha 0.10, power 0.80). Main secondary endpoints are overall response rate, disease control rate, progression free survival and quality of life. In addition, a large comprehensive translational research program will be conducted to identify novel predictive and prognostic biomarkers. The study started in December 2018. By February 2019, a total of 3 patients have been enrolled. Clinical trial information: NCT03520946.

Sign in / Sign up

Export Citation Format

Share Document